AMRI has hired Louis Yu, Ph.D., to fill the newly created position of senior vice president of quality and compliance. Dr. Yu will report to William S. Marth, AMRI's president and CEO. Dr. Yu will oversee all aspects of quality and cGMP compliance at all divisions of AMRI, including Drug Discovery Services, API and Drug Product development and manufacturing.
"AMRI has an outstanding reputation for quality service, and as we continue to expand our global network, it is critical that we continue to build on that reputation with our customers," said Mr. Marth. "Louis' deep quality experience at a number of pharmaceutical companies – both generic and branded – gives him the understanding of what our customers need. In addition, as AMRI grows toward our goal of achieving $1 billion in annual revenues by 2018, robust accountability for quality is an important business need. Louis is a welcome addition to our team."
Dr. Yu comes to AMRI with over 30 years of leadership experience in the quality and R&D functions of branded and generic pharmaceutical companies. Most recently, he served as executive vice president, global quality & compliance for Perrigo, a manufacturer of private label and branded OTC and generic Rx pharmaceutical products. There, he was responsible for strategic leadership and management of the global quality function. He led traditional quality and regulatory compliance as well as the global patient safety/medical affairs department. Prior to that, he served as vice president of quality for CV Therapeutics, now a division of Gilead. Earlier in his career, he served as the most senior quality leader at Forest Laboratories, Solvay Pharmaceuticals and Par Pharmaceutical as well as with increasing level of responsibilities in the quality and R&D organizations of the J&J Companies.